2390-59-2
CAS 2390-59-2
2390-59-2 (CAS 2390-59-2) is a pharmaceutical compound with 5 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | GI50 | 134.46014925373134 nM | 67 | - |
| - | Potency | 14989.684210526315 nM | 38 | - |
| - | IC50 | 33299.25 nM | 12 | - |
| - | AC50 | 5381 nM | 9 | - |
| - | MIC | 4843.742857142856 nM | 7 | - |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is 2390-59-2 used for in pharmaceutical contexts?
2390-59-2 (CAS 2390-59-2) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for 2390-59-2?
No adverse-event association or SIDER side-effect rows are rendered for 2390-59-2 in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is 2390-59-2 also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Basic Violet 4 with EU status "prohibited".
What clinical phase is 2390-59-2 in?
No phase 1-4 clinical development badge is rendered for 2390-59-2 because the matched compound identifier rows do not contain a max-phase value.